Articles from Science Corporation

An editorial published today in The New England Journal of Medicine (NEJM) writes that Science Corporation’s PRIMA implant is the first treatment in clinical trials to successfully restore functional vision to certain patients suffering from geographic atrophy (GA) due to age-related macular degeneration (AMD), a leading cause of blindness affecting more than 5 million people worldwide.

Science Corporation, a brain-computer interface company focused on transcending the limits of biology through neural engineering, today announced the appointment of Darius Shahida as Chief Strategy Officer, effective January 5, 2026. Shahida will lead the company's capital raising, corporate and business development, and partnership efforts. He will be based at the company’s corporate headquarters in Alameda, California and report to CEO and founder, Max Hodak.

The New England Journal of Medicine (NEJM) today published a peer-reviewed original paper with the results of a landmark clinical trial demonstrating the efficacy of Science Corporation’s PRIMA brain-computer interface (BCI) retinal implant. The paper showed that PRIMA restored functional central vision to patients suffering from geographic atrophy (GA) due to age-related macular degeneration (AMD), a leading cause of blindness affecting more than 5 million people worldwide.

Science Corporation, a leader in brain-computer interface (“BCI”) technology, has announced the preliminary clinical trials results for its PRIMA retina implant. The results showed that the implant restored real "form vision" in patients who had lost their central visual field, allowing them to execute useful, high acuity tasks like reading or recognizing faces. After receiving a PRIMA implant, patients were able to read with a clinically meaningful improvement including the ability to recognize letters.

Science Corporation (“Science”), a leader in brain-computer interface (“BCI”) technology and the developer of the Science Eye, has acquired the IP and related assets for the PRIMA retinal implant, developed by Pixium Vision SA (“Pixium”) of France, a bioelectronics BCI technology company.